Company profile
IMMUNEERING CORP
NASDAQ:IMRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ATEBIMETINIB | phase3 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05585320 | phase1_2 | active_not_recruiting | 2022-10-31 | 2026-06-01 | Immuneering Corporation | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors |
| NCT06208124 | phase1_2 | completed | 2024-02-27 | 2025-04-30 | Immuneering Corporation | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors |
| NCT07562152 | phase3 | recruiting | 2026-06-05 | 2028-06-01 | Immuneering Corporation | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
FDA applications (0)
No records yet.